Farydak (panobinostat)
- Region
- 🇪🇺 EU
- Active substance
- panobinostat
- Company
- pharmaand GmbH
- Status
- Authorised
- Therapeutic area
- Multiple Myeloma
- CHMP opinion
- Thu 25 Jun 2015
- EU approval
- Fri 28 Aug 2015
- Application
- EMEA/H/C/003725
- ATC
- L01XH03
- Official record
- www.ema.europa.eu
Indication
Farydak, in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent. Farydak, in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.
Regulatory milestones
No milestones recorded in the last year.
Follow Farydak
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.